ENVB - Enveric Biosciences, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

ENVB

ENVERIC BIOSCIENCES, INC.

NASDAQ

$1.37

▲ UP 0.00% (0.00)

KEY STATISTICS

Market Cap$817.91 K

52w High$13.63

52w Low$1.17

Dividend Yield0.33%

FrequencySpecial

P/E-0.06

Volume22.17K

Shares Out.597.01K

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Joseph Edward Tucker

COMPENSATION 2026

Salary$472,399

Stock Awards$407,142

Incentive Plan Pay$0

All Other Comp.$0

Total$879,541

ABOUT

SECTOR

Healthcare

WENT PUBLIC

May 4, 2015

METHOD OF GOING PUBLIC

Reverse Merger

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 12, 2026

DayThursday

Rev. Est.—

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2025-10-28	Reverse	1:12
2022-07-15	Reverse	1:50
2020-12-31	Reverse	1:4
2019-11-25	Reverse	1:25
2015-05-26	Reverse	1000:17609
2008-12-17	Reverse	1:10

PRICE

$1.37 ▲ UP 0.00% (+$0.00)

OVERLAYS

About Enveric Biosciences, Inc.

https://www.enveric.com ↗

Enveric Biosciences, based in Naples, Florida, develops cannabinoid medicines for cancer care, including treatments for osteoarthritis, cancer-related distress, mental health, and topical skin applications.

INDUSTRY

Biotechnology

A PRODUCT ENVERIC BIOSCIENCES, INC. IS KNOWN FOR

EB-003

Enveric's lead non-hallucinogenic neuroplastogen drug candidate aims to treat depression and anxiety by promoting neuroplasticity safely at home without psychedelic effects.